SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Hepatitis B virus splice variants are associated with and predictive of Liver cancer- Dr. P. RevillView Slideset
ACAndrea CoxMDSlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Update on Prophylactic HCV Vaccine Development- Andrea Cox, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017The Re-vival of Bile Acid Based Therapeutics for Children and Adults- Saul KarpenView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017High Efficacy and Safety of the combination HCV Regimen Grazoprevir and Elbasvir for 8 Weeks in Treatment-Naive, non-severe fibrosis HCV GT1b-Infected Patients: Interim Results of the STREAGER study- Dr. A. AbergelView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Sustained SVR 2 years after HCV treatment with simeprevir, daclatasvir and sofosbuvir in patients with portal hypertension or decompensated liver disease (not available)- Dr. E. LawitzView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Evolving Role of Real-World Evidence in NASH and HCC: From Bench to Poolside (not available)- Michael FriedView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Predicting Susceptibility and Resistance for Hepatitis B Virus Capsid Assembly Effectors- Dr. B. CoxView Slideset
ASArun SanyalMD, MBBSSlidesetViral Hepatitis and Liver DiseaseHEP DART 2017NASH Globally: Pathways to Combination Therapy, Biomarkers and Outcomes- Arun SanyalView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017A Next Generation HBV Capsid Inhibitor, AB-506: In Vitro and In Vivo Antiviral Characterization- Dr. N. ManiView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Update on Merck’s HCV Program- Mike RobertsonView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Long term follow-up after treatment with Ombitasvir/Paritaprevir/ritonavir ±Dasabuvir ±Ribavirin in the AMBER – real world experience study- Dr. R. FlisiakView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017When are we done? How long do we follow patients with advanced fibrosis or cirrhosis after SVR? (not available)- Paul PockrosView Slideset
